![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Bayer and Novartis Lose Lawsuit Against NHS Over Switch to Cheaper Eye Drug
Bayer and Novartis Lose Lawsuit Against NHS Over Switch to Cheaper Eye Drug
September 25, 2018
Bayer and Novartis lost a U.K. High Court case after challenging twelve NHS clinical commissioning groups (CCGs) that adopted a policy to offer wet age-related macular degeneration (wet AMD) patients a cheaper alternative to the companies’ Lucentis and Eylea products.
The CCGs — NHS bodies responsible for health care services for their local area — successfully defended their decision to offer certain wet AMD patients Roche’s less expensive Avastin (bevacizumab) as the preferred treatment option.
The anti-vascular endothelial growth factor treatment costs around $37, while Novartis’ Lucentis (ranibizumab) costs roughly $723 and Bayer’s Eylea (aflibercept) costs about $1,070.
Upcoming Events
-
21Oct